SBIR/STTR Research Award

Fast and Accurate Tools for Measuring Fluorescence in Living Cells

Award identifier d4b6945c99bbb5063e5114d22504241045537e529e3894d2782f1cbc06605e45Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,167,851

Program and phase

SBIR · Phase II

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MONTANA MOLECULAR LLC
Proposal award date
2014-01-15
Contract end date
2016-10-31
UEI
KN3BF8Y27ES3
Solicitation number
PA11-335
Topic code
106

Research abstract

DESCRIPTION provided by applicant Specific information about the state of second messengers in drug signaling pathways is key to understanding the mechanism of a drug within the cell The largest class of drug targets is the G Protein Coupled Receptor GPCR and over of all prescription pharmaceuticals target a GPCR These proteins are the focus of many drug discovery programs because they are therapeutic targets in a variety of areas including cancer cardiac disease diabetes central nervous system disorders inflammation and pain A critical component of many GPCR signaling pathways is the second messenger diacylglycerol DAG however there is no commercially available robust assay for DAG that can be used in either drug screening or basic research applications The challenge addressed by this proposal is to produce genetically encoded robust and easy to use live cell assay products that can be used to study and to screen for GPCR activation Phase I of this project demonstrated that it is feasible to produce extremely robust genetically encoded fluorescent sensors for DAG This discovery is significant because despite their great advantages the impact of genetically encoded assays on drug discovery has been limited because of poor signal to noise and low dynamic range of the response In Phase II the prototype sensors developed in Phase will be optimized and packaged for delivery into living cells These live cell assays will be validated under rigorous high throughput screening conditions to establish suitability for high throughput and in vivo screening applications PUBLIC HEALTH RELEVANCE New assays for biological activity are urgently needed to develop safe and effective drugs that provide better treatment outcomes and improved human health This proposal addresses the technical challenges associated with using fluorescent live cell assays and has strong potential to reduce the cost and improve the reliability of drug discovery processes

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

14 SBIR/STTR records share this UEI (2007–2025). Reported award amounts total $6,693,315. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.